Page last updated: 2024-11-12

isoleucyl-prolyl-proline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9949212
CHEMBL ID190994
CHEBI ID158716
SCHEMBL ID1646849
MeSH IDM0471979

Synonyms (17)

Synonym
(2s)-1-[(2s)-1-[(2s,3s)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid
26001-32-1
CHEBI:158716
(s)-1-[(s)-1-((2s,3s)-2-amino-3-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carboxylic acid
bdbm50169149
CHEMBL190994 ,
SCHEMBL1646849
h-ile-pro-pro-oh
l-proline,l-isoleucyl-l-prolyl-
l-isoleucyl-l-prolyl-l-proline
isoleucyl-prolyl-proline
isoleucine-proline-proline
l-proline, l-isoleucyl-l-prolyl-
mfcd08458621
HY-114424
CS-0085280
(s)-1-((s)-1-((2s,3s)-2-amino-3-methylpentanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxylic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These studies showed that there were no adverse effects of treatment at the highest doses tested."( A 90-day subchronic toxicity study and reproductive toxicity studies on ACE-inhibiting lactotripeptide.
Braun, WH; Dent, MP; Marburger, A; O'Hagan, S; Schaetti, P; Vogel, O, 2007
)
0.34
" It is derived from cow's milk, which is present in the human diet and has a safe history of consumption."( Safety evaluation of an IPP tripeptide-containing milk protein hydrolysate.
Jonker, D; Ponstein-Simarro Doorten, AY; vd Wiel, JA, 2009
)
0.35

Pharmacokinetics

ExcerptReferenceRelevance
" The aim of this study was to characterize the pharmacokinetic behavior of IPP, LPP, and VPP in a conscious pig model."( Pharmacokinetics of proline-rich tripeptides in the pig.
Deutz, NE; Duchateau, GS; Kies, AK; Ten Have, GA; van der Pijl, PC, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
" The aim of this placebo-controlled crossover study was to assess the bioavailability of Ile-Pro-Pro and 7 other ACE-inhibiting peptides present in a lactotripeptide (LTP)-enriched yogurt beverage and whether meal intake affects Ile-Pro-Pro bioavailability."( Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation.
Bianco, V; Foltz, M; Kloek, J; Koning, TM; Meynen, EE; van Platerink, C, 2007
)
0.34
"IPP and VPP were poorly absorbed and rapidly eliminated."( The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans.
Azizi, M; Blanchard, A; Lalanne, F; Peyrard, S; Wuerzner, G, 2009
)
0.35
" CasH prolonged portal bioavailability with 18 min (absorption half-life, synthetic XPP: 15 ± 2 min, CasH: 33 ± 3 min, p<0."( Enhanced Lacto-Tri-Peptide Bio-Availability by Co-Ingestion of Macronutrients.
Deutz, NE; Kies, AK; Ten Have, GA; van der Pijl, PC, 2015
)
0.42
" However, peptides display low oral bioavailability due to poor intestinal epithelial permeability and instability."( Formulation, Characterisation and Evaluation of the Antihypertensive Peptides, Isoleucine-Proline-Proline and Leucine-Lysine-Proline in Chitosan Nanoparticles Coated with Zein for Oral Drug Delivery.
Brayden, DJ; Byrne, HJ; Frías, JM; Gleeson, JP; Khalid Danish, M; Ryan, SM, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Similarly, ophthalmic changes (lenticular clouding) were observed in both control and dosed animals."( Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): V. A 13-week toxicity study of tripeptides-containing casein hydrolysate in male and female rats.
Bernard, BK; Matsuura, K; Mennear, JH; Mizuno, S, 2005
)
0.33
" This study included direct dosing of the neonates, and was designed specifically to investigate renal development and to ensure that the bioactive peptides were not associated with the same type of fetopathy exhibited by ACE inhibiting drugs."( A 90-day subchronic toxicity study and reproductive toxicity studies on ACE-inhibiting lactotripeptide.
Braun, WH; Dent, MP; Marburger, A; O'Hagan, S; Schaetti, P; Vogel, O, 2007
)
0.34
" The present study was designed as a randomized, double-blind, parallel-group, dose-response trial: 166 subjects (>140/90 mmHg) received placebo during a 2-week run-in, 8-weeks intervention followed by a 2-week washout."( Dose-dependent lowering of blood pressure by dairy peptides in mildly hypertensive subjects.
de Leeuw, PW; Koning, MM; Kroon, AA; Rennenberg, RM; van der Zander, K, 2009
)
0.35
"In a double-blind parallel group intervention study, 89 hypertensive subjects received daily peptide milk containing a low dose of tripeptides (5 mg/day) for 12 weeks and a high dose (50 mg/day) for the following 12 weeks, or a placebo milk drink to titrate the dose-response effect."( Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects.
Groop, PH; Jauhiainen, T; Kautiainen, H; Korpela, R; Rönnback, M; Vapaatalo, H; Wuolle, K, 2010
)
0.36
" The authors recently evaluated BP response using 24-hour ambulatory BP monitoring and office BP monitoring of lactotripeptides dosed twice daily in 91 previously treated and treatment-naive patients with stage 1 and stage 2 hypertension."( The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives.
Germino, FW; Hendler, SS; Neutel, J; Nonaka, M, 2010
)
0.36
" Their acute effects on BP and vascular function, important for daily dosing scheme, were studied in a placebo-controlled double-blind crossover study using a single oral dose of a fermented milk product containing Ile-Pro-Pro and Val-Pro-Pro as well as plant sterols."( Ile-Pro-Pro and Val-Pro-Pro tripeptide-containing milk product has acute blood pressure lowering effects in mildly hypertensive subjects.
Ehlers, PI; Filler, I; Jähnchen, E; Järvenpää, S; Kivimäki, AS; Korpela, R; Turpeinen, AM; Vapaatalo, H; Wagner, F; Wiegert, E, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)Ki280.00000.18003.39339.8000AID238858
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (88)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's39 (44.32)29.6817
2010's46 (52.27)24.3611
2020's3 (3.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.50 (24.57)
Research Supply Index4.75 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index20.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials26 (29.21%)5.53%
Reviews7 (7.87%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other56 (62.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]